Press Releases

Ligand Pharmaceuticals Incorporated announced the signing of a definitive merger agreement with Avista Public Acquisition Corp. II (APAC) (NASDAQ: AHPA), a publicly traded special purpose acquisition company (SPAC), providing for the spin-off of OmniAb, Inc. (OmniAb), Ligand’s antibody discovery business, immediately followed by a merger with a newly formed subsidiary of APAC. The combined company will be led by Ligand’s President, Matt Foehr, and will be renamed “OmniAb, In

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against RBB Bancorp , Amryt Pharma Plc , Cano Health, Inc.and SelectQuote, Inc. Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided. RBB Bancorp (NASDAQ: RBB) On February 18

Virpax® Pharmaceuticals, Inc., a company specializing in developing non-addictive products for pain management Post-Traumatic Stress Disorder, Central Nervous System disorders and anti-viral indications, completed all FDA required pre-clinical studies for Epoladerm™, Virpax’s investigational pre-filled topical spray analgesic product to manage chronic pain associated with osteoarthritis (OA) of the knee. The key Investigational New Drug Application (IND)-enabling studies compl

Collegium Pharmaceutical, Inc. today announced that it has completed the acquisition of BioDelivery Sciences International Inc.. “This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “We have significantly diversified the business and expanded ou

SEQENS, an integrated leader in the manufacturing of active ingredients and pharmaceutical intermediates, announced a multi-million-dollar investment in its research and development laboratory located in Devens, Mass. The improvements will ensure that the new facility will operate at the highest standards of safety and quality, while also increasing SEQENS R&D capability and productivity in the US strengthening its global R&D network. Completion of the project is expected in October 2

Axion BioSystems, a leading life sciences tools company focused on advanced live-cell assay systems, announces the acquisition of the Netherlands-based CytoSMART Technologies—an innovator in kinetic live-cell imaging analysis. The collaboration positions Axion for significant expansion in the fields of stem cell research, immuno-oncology, cell-based therapies, and drug discovery. “Since Axion BioSystems’ inception, our focus has been on developing user-centric prod

Today, Siemens signed a commercial contract and a technical agreement with Akeso Sano Pharma Co., Ltd, one of the wholly-owned subsidiaries of Akesobio, for in-depth cooperation in the field of automation, digitalization and intelligence. The cooperation aims to help Akesobio to build benchmarking projects of process automation in the field of monoclonal antibody drugs in China, which is located in Akesobio Bay Area Science and Technology Park. In addition, it will further enhance the verall

TC Biopharm (Holdings) PLC, a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announces orphan drug status has been granted for lead product OmnImmune® for use in Acute Myeloid Leukemia ("AML"). After reviewing the Phase 1b/2a trial results in relapse/refractory AML patients the FDA approved the Company's application for Orphan Drug Status. "This is another milestone achieved by

Toxys BV, a Dutch biotech company that offers a broad spectrum of innovative in vitro toxicology solutions for the safety assessment of novel medicines, (agro)chemicals, cosmetics, and food ingredients, today announces the opening of a sales office in New York (NY) and a production facility in Gaithersburg (DE) to accelerate the company’s growth. With these new facilities, Toxys will be able to better serve its clients in North America and make the Toxys assays readily available.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced it has completed enrollment of all patients in a Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis (NASH). An estimated 1.5% to 6.5% of adults in the U.S., or between 4 million and 17 million people, have NASH and about half of these also have diabetes, according to the National Institute of Diabet